Back to home
VRTX logo

Is VRTX (Vertex Pharmaceuticals Incorporated) Halal or Haram?

NASDAQ Global SelectHealthcareBiotechnology$109.41B2026-04-29
VRTX is Halal4/4 screens passed

Vertex Pharmaceuticals comfortably passes all AAOIFI Shariah screens, making it a Halal investment option. The company maintains an exceptionally low debt-to-market cap ratio of 3.5%, well below the 33% limit, and its cash and securities sit safely at 6.0%. While interest income accounts for 4.07% of revenue, it remains just under the 5% threshold, requiring Muslim investors to purify this small portion of their earnings.

Price Chart (5D)

$423.84-6.82 (-1.58%)
2026-05-012026-04-24

VRTX — Last 7 Days

DateOpenHighLowCloseVolumeChange
2026-05-01425.02427.38421.54423.92797K-0.26%
2026-04-30423.66430.95423.66427.381.1M+0.88%
2026-04-29424.44426.72419.71423.241.1M-0.28%
2026-04-28431.25431.77426.68430.14809K-0.26%
2026-04-27427.01434.07425.87426.01967K-0.23%
2026-04-24431.89433.68427.38430.291.1M-0.37%
2026-04-23440.71442.04433.81435.10778K-1.27%

Discussion

Sign in to join the discussion

Loading comments...

Shariah Screening Details for VRTX

Business Activity

Permissible

Vertex Pharmaceuticals passes the business activity screen because developing and commercializing life-saving biotechnology therapies, specifically for cystic fibrosis like TRIKAFTA and KALYDECO, is a highly permissible and beneficial activity.

Debt / Market Cap

3.55%

Debt: $3.88BThreshold: ≤33%

Interest Income

4.07%

Interest: $490.9MThreshold: ≤5%

Cash & Securities

6.04%

Cash: $6.61BThreshold: ≤33%

About Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily known for its groundbreaking therapies treating cystic fibrosis. The company develops and markets critical medications like TRIKAFTA, SYMDEKO, and KALYDECO, which target specific genetic mutations to improve patient outcomes. Its active pipeline also includes promising treatments for AAT deficiency and APOL1-mediated kidney diseases.

For Muslim investors, VRTX currently stands as a Halal investment opportunity, having successfully passed all four AAOIFI screening criteria. The company's core business of developing life-saving medical treatments aligns perfectly with Islamic values of preserving life and health. Practically, this means the stock can be confidently added to a Shariah-compliant portfolio without concerns over impermissible core operations.

From an Islamic finance perspective, Vertex boasts an incredibly strong balance sheet with a minimal debt-to-market cap ratio of just 3.5%. Its cash and interest-bearing securities also remain well within permissible limits at 6.0% of its market capitalization. However, investors should note that its interest income to revenue ratio is currently at 4.07%, which is compliant but nearing the 5% upper limit.

Because the interest income ratio is relatively close to the 5% threshold, Muslim shareholders must remain vigilant and monitor future quarterly earnings reports. Additionally, investors will need to calculate and purify the 4.07% of any dividends received to ensure their returns remain strictly Halal.

CEO

Reshma Kewalramani

Employees

6,100

IPO Date

1991-07-24

Headquarters

Boston, MA, US

VRTX Key Financial Statistics

Revenue

$12.07B

Net Income

$3.95B

EPS (Diluted)

$15.32

Stock Price

430.14

Beta

0.37

52-Week Range

362.5-510.77

Total Debt

$3.88B

Total Equity

$18.67B

Current Ratio

2.90

VRTX Financial Health & Profitability

Profit Margins

Gross Margin85.0%
Operating Margin39.4%
Net Margin32.7%

Revenue Growth (YoY)

+9.6%

Prior year: $11.02B

Net Cash

$1.21B

Cash: $5.09B — Debt: $3.88B

R&D Spending

$3.75B

% of Revenue

31.1%

Frequently Asked Questions About VRTX

Is VRTX (Vertex Pharmaceuticals Incorporated) stock halal to invest in?
Based on our AAOIFI-standard shariah screening, VRTX is Halal and considered permissible for Muslim investors. It passed all 4 of 4 compliance screens including business activity review, debt-to-market-cap ratio (3.55% vs ≤33% threshold), interest income ratio (4.07% vs ≤5% threshold), and cash & securities ratio (6.04% vs ≤33% threshold).
What does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily known for its groundbreaking therapies treating cystic fibrosis. The company develops and markets critical medications like TRIKAFTA, SYMDEKO, and KALYDECO, which target specific genetic mutations to improve patient outcomes. Its active pipeline also includes promising treatments for AAT deficiency and APOL1-mediated kidney diseases. For Muslim investors, VRTX currently stands as a Halal investment opportunity, having successfully passed all four AAOIFI screening criteria. The company's core business of developing life-saving medical treatments aligns perfectly with Islamic values of preserving life and health. Practically, this means the stock can be confidently added to a Shariah-compliant portfolio without concerns over impermissible core operations. From an Islamic finance perspective, Vertex boasts an incredibly strong balance sheet with a minimal debt-to-market cap ratio of just 3.5%. Its cash and interest-bearing securities also remain well within permissible limits at 6.0% of its market capitalization. However, investors should note that its interest income to revenue ratio is currently at 4.07%, which is compliant but nearing the 5% upper limit. Because the interest income ratio is relatively close to the 5% threshold, Muslim shareholders must remain vigilant and monitor future quarterly earnings reports. Additionally, investors will need to calculate and purify the 4.07% of any dividends received to ensure their returns remain strictly Halal. Vertex Pharmaceuticals Incorporated operates in the Healthcare sector under the Biotechnology industry and is headquartered in Boston, MA, US. The company is led by CEO Reshma Kewalramani and employs approximately 6,100 people.
What screening criteria were used for VRTX?
VRTX was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. VRTX passed 4 of these 4 screens.
Does VRTX require income purification?
Although VRTX passes all shariah screens, it does earn $490.9M in interest income (4.07% of revenue). Many scholars recommend purifying this portion by donating the equivalent percentage of any dividends received to charity. For example, if you receive $100 in dividends, you would donate approximately $4.07 to purify the income.
When was VRTX last screened?
VRTX was last screened on 2026-04-29. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.

Disclaimer

This shariah compliance assessment for VRTX (Vertex Pharmaceuticals Incorporated) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.

Other Halal Stocks in Healthcare